A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma

Trial Profile

A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Tenalisib (Primary)
  • Indications T cell lymphoma
  • Focus Pharmacokinetics
  • Sponsors Rhizen Pharmaceuticals
  • Most Recent Events

    • 19 Mar 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 19 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 29 Jan 2018 According to a Rhizen Pharmaceuticals media release, data from this trial will be presented at the 10th Annual T-Cell Lymphoma Forum 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top